Recombinant VEGF (Ranibizumab Biosimilar) 抗体
适用: 人
FACS, in vivo
宿主: 小鼠
Monoclonal
unconjugated
Fab fragment
Recombinant Antibody
-
- 抗原 See all VEGF (Ranibizumab Biosimilar) products
- VEGF (Ranibizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 片段
- Fab fragment
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This VEGF (Ranibizumab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)
- 特异性
- The Fab protein ranibizumab specifically binds to the human VEGF-A.
- 产品特性
- Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.
-
-
- 应用备注
- Functional assay, neutralization.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- VEGF (Ranibizumab Biosimilar)
- Abstract
- VEGF (Ranibizumab Biosimilar) 产品
- 别名
- MVCD1 antibody, VEGF antibody, VPF antibody, vascular endothelial growth factor A antibody, VEGFA antibody
- 物质类
- Biosimilar
- 背景
-
The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
-
You are here:
